All News
Best of 2018: Ustekinumab May be Effective in Lupus
Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory param
Read Article
Best of 2018: Unproven But Profitable Stem Cell Clinics
Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.
Read Article
Mourning the Loss of NIAMS Director Stephen Katz, MD, PhD
The following tribute to the late Dr. Steven Katz appeared on the NIH website.
Read Article
RheumNow Podcast – Rheumatologist Salaries (12.21.18)
Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.
Read Article
Zolendronate Protects Against Fracture in Osteopenia
The NEJM reports that the use of zoledronate significantly reduces the risk of nonvertebral or vertebral fragility fractures in women with osteopenia.
Read Article
Reassuring VTE Data for Tofacitinib
No significant differences in risk for venous thromboembolism (VTE) were seen in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) and those receiving tumor necrosis factor (TNF) inhibitors, analysis of administrative data showed.
Read Article
Nailfold Videocapillaroscopy in Dermatomyositis
A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM.
Read Article
Rheumatologist and Physician Salaries for 2018
Medpage Today has published the results of their 2018 Rheumatology Specialty Salaray Survey.
Read Article
TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk
Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM.
Read Article
H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis
Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.
Read Article
Rising Physician Exclusion from Medicare and Medicaid
JAMA Network Open has published that an increasing number of physicians are being excluded from Medicare and other forms of public insurance.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
David McGinnis demcginnis ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)